Related Experiment Video
Updated: Jan 13, 2026
In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
Published on: August 20, 2019
New Bioinformatic Insight into CD44: Classification of Human Variants and Structural Analysis of CD44 Targeting.
Wiktoria A Gerlicz1, Aleksandra Olczak1, Aneta M Białkowska1
1Institute of Molecular and Industrial Biotechnology, Faculty of Biotechnology and Food Sciences, Lodz University of Technology, Stefanowskiego 2/22, 90-537 Lodz, Poland.
This study clarifies the CD44 receptor variants and their interactions, identifying potential small-molecule inhibitors for cancer therapy. It aims to resolve database discrepancies and advance anti-cancer strategies targeting the CD44-hyaluronic acid axis.
Area of Science:
- Molecular Biology
- Biochemistry
- Cancer Research
Background:
- Cluster of differentiation 44 (CD44) is a hyaluronic acid (HA) receptor involved in cell adhesion, migration, and tumor progression.
- CD44 is a key biomarker for cancer stem cells, and its interaction with HA is a target for anti-cancer strategies.
- Discrepancies in CD44 variant data across protein databases hinder research.
Purpose of the Study:
- To examine and reconcile protein sequences of known CD44 variants between UniProt and NCBI databases.
- To align deposited CD44 sequences with the canonical sequence and group them by differences.
- To analyze CD44-ligand structures for identifying small-molecule inhibitors of the CD44-HA interaction.
Main Methods:
- Sequence alignment of CD44 variants against the canonical sequence.
- Comparison of CD44 variant data between UniProt and NCBI Protein databases.
- Analysis of CD44-ligand complex structures from the Protein Data Bank (PDB).
Main Results:
- Systematic examination and grouping of CD44 variants based on sequence differences.
- Identification of discrepancies and potential resolutions for CD44 variant data in public databases.
- Structural analysis to pinpoint promising small-molecule inhibitors targeting the CD44-HA interaction.
Conclusions:
- Standardizing CD44 variant data is crucial for advancing cancer stem cell research.
- Targeting the CD44-HA axis with small-molecule inhibitors presents a viable anti-cancer therapeutic strategy.
- This work provides a foundation for developing more effective cancer treatments by clarifying CD44 receptor characteristics.
More Related Videos
07:35Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
Published on: October 11, 2018
08:04Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
Published on: June 6, 2025